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PODIUM SESSION III: MODELING STUDIES
MO1
IMPACT OF INCLUDING CARDIOVASCULAR AND RESPIRATORY 
OUTCOMES ON ESTIMATES OF CLINICAL AND ECONOMIC BENEFITS
OF INFLUENZA VACCINATION IN THE U.S. ELDERLY POPULATION
Gao X1, Snedecor SJ1, Ethgen O2, Botteman MF1
1PharMerit North America LLC, Bethesda, MD, USA, 2GSK Biologicals, Rixensart, Belgium
OBJECTIVES: Inﬂ uenza virus activity increases hospitalizations for a broad range of 
cardiopulmonary diagnoses, including pneumonia and inﬂ uenza (P&I). However, only
a few economic studies have even partially incorporated broader respiratory (including
P&I) and cardiovascular outcomes (R&C) in assessing vaccination effects. We devel-
oped a conceptual model that assessed the costs and beneﬁ ts of vaccinating elderly
individuals from a US societal perspective based on 2 different outcomes (P&I only
vs. R&C). METHODS: A literature-based decision model was used to estimate the 
short- and long-term costs and quality-adjusted life expectancy (QALE) associated
with annual inﬂ uenza vaccination for the elderly population (aged q 65 years, N 
37,888,000). One version of the model included P&I outcomes only whereas the other 
version included the broader inﬂ uenza-related R&C outcomes. The reduction rate
of inﬂ uenza due to vaccination was 30% and applied to the probability of seeking 
medical attention, antivirals and antibiotics utilization, and indirect costs. The reduc-
tion in hospitalization due to inﬂ uenza was calibrated to reﬂ ect recent epidemiologic 
estimates. RESULTS: When only P&I were modeled, the number of hospitalizations
was 63,000 and 88,000 with and without vaccination, respectively. The QALE per
person was 7.7514 versus 7.7509 years; and the average cost per person was $118 
versus $121, respectively. When R&C were modeled, the number of hospitalizations
increased to 180,000 and 239,000; the QALE per person decreased to 7.7392 and
7.7355; and the average cost increased to $325 and $388, respectively, with and 
without vaccination. The inclusion of all R&C outcomes improved the estimated 
vaccination beneﬁ ts, with more hospitalizations avoided (34,000), QALE gained
(123,000 QALYs), and cost savings ($2 billion). Results were similar in sensitivity
analyses. CONCLUSIONS: Excluding R&C outcomes considerably underestimates 
the burden of inﬂ uenza and the economic beneﬁ ts of inﬂ uenza vaccination. Future
economic assessments of inﬂ uenza vaccination strategies should include all R&C 
outcomes.
MO2
A SYSTEMATIC EVALUATION OF EMPIRICAL BAYES METHODS 
UNDER TIME CENSORED CONDITIONS
Murray JF1, Fryback DG2
1Eli Lilly and Company, Indianapolis, IN, USA, 2University of Wisconsin – Madison, Madison, 
WI, USA
OBJECTIVES: Quality assurance must identify problems among a group of providers 
using sparse observations within some providers, posing problems of estimation. We 
compare Empirical Bayes (EB) methods for estimating means and conﬁ dence intervals
to classical statistical estimates when time frames are censored. METHODS: Retrospec-
tive data on four measures with various units of analysis were selected: (1) quality of 
care for psychiatric emergencies by physicians, (2) cesarean sections rates in hospitals,
(3) LOS for ﬁ ve DRGs in hospitals, and (4) “cost” for ﬁ ve DRGs by hospital. Data 
was available for overall time frames of one to two years. Individual unit of analysis 
results from the overall time frame were assumed as the “best” estimate of true per-
formance. Data sets were subset into shorter time periods (i.e., months or quarters).
EB priors were estimated by averaging results across units of analysis within each cen-
sored time frame. Priors were combined with the observed data to form posterior esti-
mates for individuals; bootstrap methods were used to estimate Bayesian conﬁ dence 
intervals. Bayesian and Classical estimates of means and conﬁ dence intervals were 
compared within and across time periods by units of analysis on four measures of 
“goodness”: (1) Absolute difference between the “true” mean and the classical and EB
estimates, (2) frequency of the EB mean being closest to the “true” mean, (3) average 
widths of the EB and classical intervals, and the actual probability coverage of the
estimated intervals. RESULTS: EB methods were consistently closer in absolute differ-
ence and by frequency to the “true” mean. EB conﬁ dence intervals were consistently 
narrower giving less uncertainty about the location of the true mean while maintaining 
the expected probability coverage. CONCLUSION: Empirical Bayes methods can 
mitigate the adverse effect of sparse samples at the provider level compared to classical 
estimation for quality assurance when limited time constrains observations.
MO3
INTEGRATING INDIVIDUAL PATIENT LEVEL RCT DATA WITH A
COMPREHENSIVE DECISION ANALYTIC COST EFFECTIVENESS MODEL
Manca A1, Saramago P1, Henriksson M2
1University of York, York, UK, 2Linköping University, Linköping, Sweden
OBJECTIVES: Randomised controlled trials (RCTs) are the gold standard for demon-
strating the efﬁ cacy of medical interventions. However, RCTs may be neither sufﬁ cient
nor the most efﬁ cient vehicle to generate cost effectiveness (CE) evidence to inform 
health care resource allocation decisions. RCT evidence may a) not be directly relevant 
to a given jurisdiction; b) exclude relevant treatment strategies; c) be too short in follow 
up. Comprehensive decision-analytic models (CDAMs) can help address the above 
challenges. These models are typically populated using summary measures, and often 
require strong distributional assumptions concerning their input parameters. We 
extend the use of CDAM, to accommodate and exploit the wealth of information 
contained in an individual patient-level dataset (IPD). METHODS: Using the UK 
RITA-3 trial, we show how to conduct a Bayesian analysis of IPD with the aim to a)
estimate input parameters to populate a CDAM, and b) inform probabilistic sensitivity 
analysis (PSA) to evaluate the decision problem. The proposed framework allows
simultaneous estimation of a system of risk equations for speciﬁ c events of interest, 
estimation of costs and quality of life implications related to the occurrence of these 
events, and PSA into a single CE model. Results are compared and contrasted with 
those from a standard two-stage approach, i.e. estimation of parameters through clas-
sical statistical inference, followed by PSA in a spreadsheet. RESULTS: Using IPD
within the proposed analytical framework produced more accurate estimates than the 
standard two-stage approach in terms of posterior distributions of the incremental costs
and QALYs. This resulted in a reduced decision uncertainty, as represented by the CE 
acceptability curve. CONCLUSIONS: CDAM based on IPD looks more promising and 
appropriate from the methodological point of view than standard (two-stage) model-
ling methods. This general analytical framework can be further extended to facilitate 
statistical evidence synthesis in the presence of multiple data sources.
MO4
RE-EXAMINING THE SPECIFICATION OF REGRESSION MODELS OF
MULTINOMIAL RESPONSES: AN APPLICATION TO PREDICTING POST-
STROKE DISCHARGE DISPOSITION
Bergtold J1, Onukwugha E2
1Kansas State University, Manhattan, KS, USA, 2University of Maryland School of Pharmacy, 
Baltimore, MD, USA
Current approaches to specifying multinomial logistic models (MLM) have not high-
lighted the statistical adequacy of the model speciﬁ cation or the implications of pos-
sible misspeciﬁ cation due to patterns common to observational data. The probabilistic 
reduction (PR) approach provides a framework to guide model speciﬁ cation when 
using observational data. OBJECTIVE: The objective of this study is to examine the
speciﬁ cation of MLM using the PR approach, with an application to identifying pre-
dictors of hospital discharge disposition among stroke patients. METHODS: Within 
the PR approach, the index function associated with the choice probability is function-
ally related to the inverse conditional distribution. Operationalization of the index 
function leads to the consideration of nonlinear terms and interacted terms, based on 
the inverse conditional distribution and the existence of dependence across model 
covariates. To illustrate the methodology, an empirical application examined predic-
tors of hospital discharge disposition among live discharges of adult stroke patients 
in Maryland using a population-based discharge dataset (N  79,561). Categories of 
discharge disposition included home, home health care, rehabilitation, nursing home, 
discharges against medical advice, and ‘all other’. Covariates controlled for patient
demographic and clinical characteristics. A traditional MLM speciﬁ cation and a model 
speciﬁ ed following the PR approach were estimated and compared. RESULTS: Results 
based on the information criteria (traditional speciﬁ cation: AIC  194377.1 and AICC:
194377.2; PR speciﬁ cation: AIC  192705.5 and AICC: 192738.1) estimates and the 
likelihood ratio test (p-value  0.000) showed that the PR approach provides a better 
ﬁ t and that the traditional speciﬁ cation of the model is misspeciﬁ ed. We also estimate
marginal effects of the explanatory variables on the probability of each discharge 
category. CONCLUSION: The novel ﬁ nding is that the PR approach can be used to 
specify discrete choice models that provide a better ﬁ t to observational data, compared 
to models speciﬁ ed using more common approaches.
PODIUM SESSION III: NEUROLOGICAL DISORDERS – 
Outcomes Research & Health Care Policy Studies
ND1
COST–EFFECTIVENESS OF DISEASE–MODIFYING THERAPY FOR 
MULTIPLE SCLEROSIS: A POPULATION–BASED EVALUATION
Noyes K1, Bajorska A1, Chappel AR2, Schwid S1, Mehta LR2, Holloway R1, Dick A3
1University of Rochester School of Medicine, Rochester, NY, USA, 2University of Rochester, 
Rochester, NY, USA, 3The RAND Corporation, Pittsburgh, PA, USA
OBJECTIVES: Costly disease modifying therapies (DMTs: interferon beta-1a and 
beta-1b and glatiramer acetate) were introduced in the 1990s to reduce the frequency 
of relapses and to slow disease progression in patients with multiple sclerosis (MS).
At the same time, these therapies are characterized by uncomfortable side effects and 
high costs. This study examines data from a 2000–2005 population-based survey of 
MS patients from the Sonya Slifka Study to evaluate the cost-effectiveness (CE) of 
DMTs in the US compared to no DMT. METHODS: We generated 10-year disease 
progression paths using ﬁ rst-order Markov models to estimate transitional probabili-
ties and logistic models to estimate relapse rates based on published estimates of DMT 
treatment effects. To estimate costs, we used Medicare rates for reported utilization 
events. Outcomes were measured as gains in quality-adjusted life years (QALY) and
relapse-free years, differences in the number of disease progressions (as measured by 
disability status), and gains in years spent in lower disability states. Monte Carlo (n 
 50) simulations, resampling (n  250) methods, and sensitivity analyses were con-
ducted to evaluate uncertainty. RESULTS: Using DMT for 10 years resulted in signiﬁ -
cant health gains. The choice of the optimal therapy depends on the outcome, with 
interferons generating the highest QALY gain (0.187 QALY), fewer disease progres-
sions (by 0.91), fewer years spent in higher disability states (by 0.81 year), and leading 
to more relapse-free years (by 1.12 year) compared to glatiramer or no DMT. The 
CE of all DMTs exceeded $1,000,000/QALY, with glatiramer being the most cost-
ineffective ($5,209,524/QALY). As the cost of DMT decreases, DMTs become more 
A14 Abstracts
cost-effective. CONCLUSIONS: While the current practice of recommending DMT 
for any patient with progressive MS results in substantial health gains, these gains
come at a very high drug cost, rendering the incremental cost-effectiveness ratios of 
each of the DMTs far above currently accepted standards.
ND2
DIRECT HEALTH CARE AND WORKLOSS BURDEN OF CHEMOTHERAPY–
ASSOCIATED PERIPHERAL NEUROPATHY IN BREAST, OVARIAN, HEAD
AND NECK, AND NON–SMALL CELL LUNG CANCER
Pike C1, Birnbaum HG1, Kaufman R1, Muehlenbein CE2, Pohl G2, Natale R3
1Analysis Group, Inc, Boston, MA, USA, 2Eli Lilly and Company, Indianapolis, IN, USA, 3Cedars-
Sinai Outpatient Cancer Center, Los Angeles, CA, USA
OBJECTIVES: Chemotherapy-associated peripheral neuropathy (CAPN) is a painful 
side-effect of chemotherapy. Comprehensive measures of health outcomes, medical
costs, and workloss burden of CAPN in patients with breast, ovarian, head/neck, or
non-small cell lung cancer (NSCLC) have not been quantiﬁ ed. This study assesses the
outcomes and direct and indirect cost burden of CAPN in these four tumor types from 
a third-party payer perspective. METHODS: Data were from an administrative claims
database of privately insured companies covering 1999–2006. Patients with qualifying 
tumors, and claims for chemotherapy and services indicative of peripheral neuropathy 
(PN) within 9-months of chemotherapy were selected. Cases were matched 1:1 to
controls with no PN-related claims based on cancer type, diabetes history, demograph-
ics, and propensity for reporting PN claims during the study period (estimated on
baseline resource use and comorbidities). Direct costs and resource use were calculated 
for a 12-month study period using diagnosis and procedure codes, pharmacy claims,
and provider specialty codes. Indirect costs were obtained for a subset of patients that
had disability and medically related absenteeism data. Comparisons of cost and
resource use between cases and controls used paired t-tests. RESULTS: Among patients
treated for breast, ovarian, head/neck, and NSCLC, 454 were identiﬁ ed who met 
inclusion criteria and had evidence of CAPN. Average direct costs were $17,344 higher
for CAPN cases than non-CAPN controls (p  0.0001). Outpatient costs were the 
highest component for both cases and controls with cases having excess outpatient
costs of $8092 (p  0.001). On average, each CAPN case had 12 more outpatient 
visits than controls (51.3 vs. 39.8 visits; p  0.0001), and spent more days in the hos-
pital (5.6 vs. 3.2 days; p  0.001). Indirect resource use and costs were higher for
cases but not statistically different from controls. CONCLUSIONS: CAPN is associ-
ated with increased direct medical cost and resource use of patients with breast,
ovarian, head/neck, or NSCLC.
ND3
PRESCRIBING PATTERNS AMONG DEMENTIA PATIENTS AT THE
VETERANS AFFAIRS MARYLAND HEALTH CARE SYSTEM (VAMHCS)
Rattinger GB1, DeLisle S2, Onukwugha E1, Mullins CD1
1University of Maryland School of Pharmacy, Baltimore, MD, USA, 2University of Maryland
School of Medicine and VA Maryland Health Care System, Baltimore, MD, USA
OBJECTIVES: Dementia patients often receive cholinesterase inhibitors and/or 
memantine (CIM) for cognitive symptoms, and antidepressants (AD) for behavioral 
symptoms. Ideally, patient demographics or clinic locations have no effect on care
received. We explored whether patient demographics and/or outpatient referrals to
specialized dementia or mental health clinics inﬂ uenced the likelihood of receiving 
CIM/AD medications. METHODS: Veteran’s Affairs Maryland Health Care System 
(VAMHCS) electronic medical records were used to select a cohort, based on diagnosis 
codes or medications indicating Alzheimer’s or related dementias. Patients aged 60 
and above, with index dates after 1999 were selected. Additional criteria included:
minimum of one year follow up or death within a year of index date. The outcome
(referent) was categorized as: receipt of CIM, receipt of AD, receipt of both CIM/AD 
(receipt of neither medication type). Multivariable multinomial logistic models (MLM)
explored predictors of CIM and AD utilization categories, including age, time in
cohort, race, marital status, and referrals to dementia or mental health clinics.
RESULTS: A cohort of 1359 patients, average age of 78.1 (SD 6.0) years and 22% 
African-Americans, was followed up for an average of 3.1 (SD 1.9) years. Thirty-ﬁ ve
percent had mental health or dementia clinic visits while 18% visited both clinics.
Signiﬁ cant associations were found for receiving both CIM and AD medications versus 
receiving no medication for years in cohort (OR  1.237, p  0.0001), African-Ameri-
can race (OR  0.437, p  0.0001), age (OR  0.966, p  0.0288),) marital status 
(OR  1.492, p  0.0339) and mental health clinic visit (OR  3.386, p  0.0001). 
Dementia clinic visit was associated with CIM only but not receipt of both medications
(OR  1.405, p  0.0996). CONCLUSIONS: In veterans with possible dementia, 
demographic factors and care at dementia/mental health clinics impact the likelihood 
of receiving CIM/AD medications. These found associations need to be further inves-
tigated for their potential impact on patient outcome.
ND4
COST–UTILITY OF INTERFERON BETA–1B IN THE TREATMENT OF
PATIENTS WITH A CLINICALLY ISOLATED SYNDROME SUGGESTIVE OF
MULTIPLE SCLEROSIS: MODEL UTILIZING FIVE YEAR BENEFIT DATA
Caloyeras JP1, Harrow B1, Wang C2, Beckmann K3, Knappertz V2, Pohl C3, Miller JD1, 
Russell MW1, Sandbrink R3, Gondek K2
1Abt Bio-Pharma Solutions, Inc, Lexington, MA, USA, 2Bayer Healthcare Pharmaceuticals Inc, 
Montville, NJ, USA, 3Bayer Schering Pharma AG, Berlin, P300, Germany
OBJECTIVES: To estimate the cost-utility of interferon-beta-1b (IFNB-1b) for the
treatment of patients with a clinically isolated syndrome (CIS) suggestive of multiple
sclerosis (MS) using ﬁ ve year BENEFIT clinical trial data. METHODS: We developed 
a Markov model of the epidemiology and treatment of CIS and MS. A hypothetical 
cohort of 1000 patients with incident CIS, with initial health states deﬁ ned by Kurtz-
ke’s Expanded Disability Symptom Scale (EDSS), was speciﬁ ed. The cohort was
assumed to be treated with either IFNB-1b (250 mcg eod) following an initial demye-
linating event suggestive of MS or not treated until conﬁ rmation of Poser-deﬁ ned MS. 
Data from BENEFIT were used to model EDSS transitions and transition from CIS 
to MS. Relapses were estimated from BENEFIT and published natural history data.
Following transition to MS, all patients were assumed to be treated with IFNB-1b
until reaching EDSS 6.5. Direct and indirect medical costs of MS treatment and IFNB-
1b were estimated using published literature and pricing schedules. Patient utilities
were derived from EQ-5D data from BENEFIT, supplemented by published data 
deﬁ ned by EDSS score and relapse occurrence. Mortality was estimated using life 
tables and EDSS data. Costs (2007 AUD) and outcomes were discounted at 5% per 
annum. Sensitivity analyses were performed on all key model parameters. RESULTS:
Use of IFNB-1b was associated with fewer EDSS transitions, longer time to CDMS
diagnosis, and a reduced relapse burden. In the base case (Australian perspective; 25-
year time horizon), the incremental cost utility of IFNB-1b versus no treatment was 
AUD 20,000 (USD 14,000) per quality-adjusted life year (QALY) gained. Findings 
were sensitive to time horizon, IFNB-1b cost and treatment effect, and underlying 
rate of disease progression. CONCLUSIONS: This model shows that IFNB-1b treat-
ment of patients with CIS is cost-effective with a cost per QALY gained within the 
range of many well accepted health care interventions.
PODIUM SESSION IV: HEALTH CARE MANAGEMENT STUDIES
HM1
EFFICIENCY AND ECONOMIC BENEFITS ASSOCIATED WITH THE USE
OF A PAYER–BASED ELECTRONIC HEALTH RECORD IN AN EMERGENCY
DEPARTMENT AMONG A HEALTH INSURED POPULATION
Daniel GW1, Ewen E2, Willey VJ3, Shirazi M4, Malone DC5
1HealthCore, Wilmington, DE, USA, 2Christiana Care Health System, Newark, DE, USA, 
3University of the Sciences in Philadelphia, Philadelphia, PA, USA, 4University of Arizona
College of Medicine, Tucson, AZ, USA, 5University of Arizona College of Pharmacy, Tucson, 
AZ, USA
OBJECTIVES: Health information exchange technologies are being implemented
widespread with goals of improving efﬁ ciency and costs of care. The need for timely, 
accurate, and pertinent information is most critical in the emergency department (ED).
This study evaluated the use of a payer-based electronic health record (P-EHR), which 
includes a clinical summary of a patient’s medical and pharmacy claims, in an ED on
length of stay (LOS) and costs of care among a commercially insured population. 
METHODS: A large urban hospital implemented a P-EHR in the ED. The P-EHR 
was evaluated using administrative claims and supplemental hospital data. Encounters
with P-EHR use were identiﬁ ed from claims between September 1, 2005 and February 
17, 2006. Accounting for seasonal variation, historical comparison encounters were
identiﬁ ed from November 1, 2004 to March, 31, 2005. Outcomes included ED LOS 
and cost for the ED encounter. Control variables included age, gender, pre-encounter
six month health care utilization and costs, comorbidity burden, plan type, day of 
week (weekend vs weekday), primary diagnosis, triage severity scores, and ED census. 
Analyses used multivariate generalized linear models and non-parametric bootstrap
for standard errors of predictions. RESULTS: A total of 2288 ED encounters were 
analyzed (779 P-EHR/1509 comparison). ED-only P-EHR encounters were discharged 
19 minutes quicker (95%CI:5–33 minutes) as compared to encounters not associated 
with the P-EHR. Among encounters resulting in hospitalization, the P-EHR was 
associated with a 77 minute reduction in LOS (95%CI:28–126 minutes) as compared
to non-P-EHR encounters. The use of the P-EHR was also associated with $1560 
(95% CI:$43–$2910) savings in total plan expenditures for encounters resulting in 
hospitalization. No signiﬁ cant difference in costs was observed among ED-only 
encounters. CONCLUSIONS: This study highlights that a P-EHR can have a meaning-
ful impact on ED throughput and costs. These beneﬁ ts may translate into improvement
in the care provided to patients and their satisfaction.
HM2
USING DECISION MODELING TO MAP PHARMACISTS INTERVENTIONS 
TO OUTCOMES FOR PATIENTS WITH DIABETES
Pinto SL, Bechtol R, Zhang YJ
University of Toledo, Toledo, OH, USA
OBJECTIVES: To determine the cost savings resulting from speciﬁ c pharmacist inter-
ventions provided to patients with diabetes and their physicians, using a decision-
analysis modeling approach. METHODS: Prospective, cohort study using Lucas
County employees with diabetes enrolled in an employer-sponsored Medication
Therapy Management program in Northwest Ohio. An expert (comprising of clinical 
pharmacists and researchers) opinion guided clinical model pathway was developed to 
identify and map speciﬁ c pharmacist interventions to corresponding responses and
outcomes. Interventions included: 1) alerting physician of patient’s abnormal A1c 
and/or blood sugar proﬁ le; 2) pattern management; 3) instructing on the proper use of 
injectable; 4) glucometer training; 5) advising patients on best way to correct hypogly-
cemic/hyperglycemic episodes. Data was extracted from patient charts and entered into
Microsoft Excel. A 1-year decision-analytic model was constructed using The TreeAge
Pro Suite 2008 to identify the cost-savings per intervention. Probabilities for the inter-
ventions, responses, and outcomes were obtained from real-world data. For example,
